Rockville , Sept. 05, 2023 (GLOBE NEWSWIRE) -- The global hormone replacement therapy (HRT) market is valued at US$ 22.5 billion in 2023 and is forecasted to expand at a CAGR of 6.8% from 2023 to 2033. Japan, India, China, and the United Kingdom are estimated to emerge as some of the most opportune markets for hormone replacement therapy providers.
Women have become more aware of menopausal symptoms than ever before and amidst this, hormone replacement therapy has emerged as a preferred choice of treatment for the same. The growing use of hormone replacement therapy for the treatment of osteoporosis and dementia is also anticipated to offer a plethora of new opportunities for HRT providers over the next ten years.
Get Free Sample Copy of This Report:
https://www.factmr.com/connectus/sample?flag=S&rep_id=2224
| Report Attributes | Details |
| Historical Data | 2023 - 2033 |
| Value Projection (2033) | US$ 43.7 Billion |
| Growth Rate (2023-2033) | 6.8% CAGR |
| No. of Pages | 170 pages |
| No. of Tables | 80 Tables |
| No. of Figures | 219 Figures |
Key Takeaways from Market Study
- Demand for hormone replacement therapy is projected to expand at a CAGR of 6.8% from 2023 to 2033.
- The global hormone replacement therapy market is anticipated to reach a value of US$ 43.7 billion by 2033.
- Increasing investments in medical R&D, growing awareness regarding the benefits of hormone replacement therapy, high availability of favourable reimbursement for hormone therapies, and expanding geriatric population are prime market drivers.
- The carcinogenic effect of combination hormone replacement therapy and the high cost of certain HRT products are key market restraints.
- At present, North America accounts for around 25% of the global market share.
- Estrogen hormone replacement therapy is projected to lead global revenue generation through 2033.
Key Companies Profiled in This Report
- Novo Nordisk A/S
- Bayer AG
- Endo International Plc
- Janssen NV
- Mithra Pharmaceuticals
- Novartis AG
- Pfizer Inc.
- Allergen Plc
- Merck KGaA
- Teva Pharmaceuticals
- Mylan N.V.
“Growing senescent population to act as key catalyst for hormone replacement therapy market growth in the future,” says a Fact.MR analyst
Winning Strategy
Hormone replacement therapy providers are investing in research and development to develop novel therapies for the treatment of various chronic diseases that allow them to expand their business potential on a global scale. Companies are also opting for other organic and inorganic strategies to boost their revenue generation potential around the world.
This detailed hormone replacement therapy market research analysis by Fact.MR, a market research and competitive intelligence provider sheds light on all strategies adopted by established as well as incoming companies to give them a comprehensive understanding of the global market landscape.
Get Customization on this Report for Specific Research Solutions:
https://www.factmr.com/connectus/sample?flag=RC&rep_id=2224
Key Segments of Hormone Replacement Therapy Industry Research Report
- By Therapy Type
- Estrogen Hormone Replacement Therapy
- Thyroid Replacement Therapy
- Growth Hormone Replacement Therapy
- By Dosage Form
- Tablets
- Patches
- Injections
- Implants
- Creams
- Others
- By Indication
- Menopause
- Osteoporosis
- Thyroid
- Growth Hormone Deficiency
- By Sales Channel
- Hospital Pharmacies
- Clinics
- Retail Pharmacies
- Online Pharmacies
- By Region
- North America
- Latin America
- Europe
- APAC
- MEA
Explore More Related Studies Published by Fact.MR Research:
Bio-identical Hormones Replacement Therapy Market: The bio-identical hormones replacement market is likely to grow at a CAGR of 5.1% through 2032.
Aesthetic Medicine Market: Value of aesthetic medicines are projected to increase at a CAGR of around 10.3% during 2022 – 2032.
Brain Monitoring Devices Market: The global brain monitoring devices market is currently valued at US$ 6.5 billion and is expected to increase at a noteworthy CAGR of 6% to reach US$ 8.7 billion by the end of 2027.
More Valuable Insights on Offer
Fact.MR, in its new offering, presents an unbiased analysis of the global hormone replacement therapy market, presenting historical demand data (2018 to 2022) and forecast statistics for the period (2023 to 2033).
The study divulges essential insights on the market based on therapy type (estrogen hormone replacement therapy, thyroid replacement therapy, growth hormone replacement therapy), dosage form (tablets, patches, injections, implants, creams, others), indication (menopause, osteoporosis, thyroid, growth hormone deficiency), and sales channel (hospital pharmacies, clinics, retail pharmacies, online pharmacies), across five major regions of the world (North America, Europe, Asia Pacific, Latin America, and MEA).
About Fact.MR:
Fact.MR is a distinguished market research company renowned for its comprehensive market reports and invaluable business insights. As a prominent player in business intelligence, we delivers deep analysis, uncovering market trends, growth paths, and competitive landscapes. Renowned for its commitment to accuracy and reliability, we empowers businesses with crucial data and strategic recommendations, facilitating informed decision-making and enhancing market positioning. With its unwavering dedication to providing reliable market intelligence, FACT.MR continues to assist companies in navigating dynamic market challenges with confidence and achieving long-term success. With a global presence and a team of experienced analysts, FACT.MR ensures its clients receive actionable insights to capitalize on emerging opportunities and stay ahead in the competitive landscape.
Contact:
US Sales Office
11140 Rockville Pike
Suite 400
Rockville, MD 20852
United States
Tel: +1 (628) 251-1583, +353-1-4434-232 (D)
Sales Team: sales@factmr.com
Follow Us: LinkedIn | Twitter | Blog
